Pharmacological treatment of type 1 autoimmune pancreatitis
10.3760/cma.j.cn115667-20251016-00149
- VernacularTitle:1型自身免疫性胰腺炎的药物治疗
- Author:
Zonghao LIU
1
;
Chunhua ZHOU
1
;
Duowu ZOU
1
Author Information
1. 上海交通大学医学院附属瑞金医院消化内科，上海 200025
- Publication Type:Journal Article
- Keywords:
Autoimmune pancreatitis type 1;
Drug treatment;
Glucocorticoid
- From:
Chinese Journal of Pancreatology
2025;25(5):321-326
- CountryChina
- Language:Chinese
-
Abstract:
Type 1 autoimmune pancreatitis is a chronic inflammatory disease characterized by chronic inflammation and fibrosis of the pancreas. Currently, classical therapies (e.g., glucocorticoids, monoclonal antibodies, and immunomodulators) play a key role in inducing disease remission and maintaining long-term efficacy, but are often accompanied by significant drug side effects. In recent years, biologics and small-molecule targeted drugs become a new direction for the treatment of type 1 autoimmune pancreatitis due to their higher targeting and potential efficacy. This article systematically summarizes the major pharmacological advances in the treatment of type 1 autoimmune pancreatitis, with the aim of providing references and insights for clinical management and the development of new therapies.
